Today: 27 February 2026
Subscribe
Browse Category

NASDAQ:GPCR 8 December 2025 - 15 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
····
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
13 January 2026
····
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics shares fell about 6% to $60.73 Tuesday, swinging between $58.95 and $65.69 intraday after recent gains. The drop followed positive Phase 2b results for its oral obesity drug aleniglipron and a $747.5 million equity raise. Trading volume was below average, with some reports noting declines up to 9% during the session.
16 December 2025
···
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics shares doubled to $69.98 mid-day December 9 after reporting strong Phase 2b data for its oral obesity drug, aleniglipron. The 120 mg dose showed 11.3% placebo-adjusted weight loss over 36 weeks; higher doses reached 15.3%. No drug-induced liver injury or QTc prolongation was reported. Market cap stands near $4 billion, with the stock trading close to its 52-week high.
9 December 2025
··
Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Structure Therapeutics shares closed at $69.98 on December 9, 2025, up 102% after positive Phase 2b trial results for its oral obesity drug aleniglipron. The stock hit a new 52-week high of $94.90 intraday, pushing market value to $4.25 billion. The company announced a $500 million equity offering following the surge. Aleniglipron showed up to 15.3% placebo-adjusted weight loss in studies.
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.
9 December 2025
······
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics shares surged 101% to $69.46 on December 8 after reporting positive Phase 2b data for aleniglipron, its oral GLP-1 agonist for obesity. Patients on 120 mg lost 12.1% of body weight at 36 weeks versus 0.8% for placebo. The company held $799 million in cash as of September 30.
8 December 2025
···
Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks were little changed Monday ahead of the Federal Reserve meeting, with the S&P 500 and Dow down 0.03% and the Nasdaq 100 up 0.07%. Small-cap stocks surged, led by biotech firms on clinical trial results and M&A news. Cemtrex soared 134%, Structure Therapeutics 97%, and Wave Life Sciences 92%. The Russell 2000 rose 0.55% intraday.
8 December 2025
········
Go toTop